Transcriptional Profile of Ki-Ras-Induced Transformation of Thyroid Cells

REFERENCES

• Hedinger C., Williams E. D., Sobin L. H. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989; 63(5)908–911
   PubMed Web of Science ®Google Scholar
• Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat. Rev. Cancer 2002; 2(7)543–549
   PubMed Web of Science ®Google Scholar
• Maxon H. R., Thomas S. R., Saenger E. L., Buncher C. R., Kereiakes J. G. Ionizing irradiation and the induction of clinically significant disease in the human thyroid gland. Am. J. Med. 1977; 63(6)967–978
   PubMed Web of Science ®Google Scholar
• Takeichi N., Ezaki H., Dohi K. A review of forty-five years study of Hiroshima and Nagasaki atomic bomb survivors. Thyroid cancer: reports up to date and a review. J. Radiat. Res. 1991; 32: 180–188, (Suppl)
   PubMedGoogle Scholar
• Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365(6447)649–651
   PubMed Web of Science ®Google Scholar
• O'Sullivan C., Barton C. M., Staddon S. L., Brown C. L., Lemoine NR. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol. Carcinog. 1991; 4(5)345–349
   PubMed Web of Science ®Google Scholar
• Nikiforov Y. E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 2002; 13(1)3–16
   PubMed Web of Science ®Google Scholar
• Santoro M., Melillo R. M., Carlomagno F., Fusco A., Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann. NY Acad. Sci. 2002; 963: 116–121
   PubMed Web of Science ®Google Scholar
• Pierotti M. A., Bongarzone I., Borrello M. G., Mariani C., Miranda C., et al. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J. Endocrinol. Invest. 1995; 18(2)130–133
   PubMed Web of Science ®Google Scholar
• Kimura E. T., Nikiforova M. N., Zhu Z., Knauf J. A., Nikiforov Y. E., et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63(7)1454–1457
   PubMed Web of Science ®Google Scholar
• Ciampi R., Knauf J. A., Kerler R., Gandhi M., Zhu Z., et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 2005; 115(1)94–101
   PubMed Web of Science ®Google Scholar
• Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992; 52(5)1369–1371
   PubMed Web of Science ®Google Scholar
• Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 1993; 91(4)1753–1760
   PubMed Web of Science ®Google Scholar
• Fagin J. A., Matsuo K., Karmakar A., Chen D. L., Tang S. H., Koeffler H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993; 91(1)179–184
   PubMed Web of Science ®Google Scholar
• Lemoine N. R., Mayall E. S., Wyllie F. S., Williams E. D., Goyns M., et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4(2)159–164
   PubMed Web of Science ®Google Scholar
• Namba H., Rubin S. A., Fagin J. A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 1990; 4(10)1474–1479
   PubMed Web of Science ®Google Scholar
• Vasko V., Ferrand M., Di Cristofaro J., Carayon P., Henry J. F., de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 2003; 88(6)2745–2752
   PubMed Web of Science ®Google Scholar
• Lemoine N. R., Staddon S., Bond J., Wyllie F. S., Shaw J. J., Wynford-Thomas D. Partial transformation of human thyroid epithelial cells by mutant Ha-ras oncogene. Oncogene 1990; 5(12)1833–1837
   PubMed Web of Science ®Google Scholar
• Fusco A., Berlingieri M. T., Di Fiore P. P., Portella G., Grieco M., Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell Biol. 1987; 7(9)3365–3370
   PubMed Web of Science ®Google Scholar
• Portella G., Ferulano G., Santoro M., Grieco M., Fusco A., Vecchio G. The Kirsten murine sarcoma virus induces rat thyroid carcinomas in vivo. Oncogene 1989; 4(2)181–188
   PubMed Web of Science ®Google Scholar
• Santelli G., de Franciscis V., Portella G., Chiappetta G., D'Alessio A., et al. Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter. Cancer Res. 1993; 53(22)5523–5527
   PubMed Web of Science ®Google Scholar
• Bos J. L. Ras oncogenes in human cancer: a review. Cancer Res. 1990; 49(17)4682–4689, Erratum in: 1990 Cancer Res. 1990 50 (4), 1352
   Web of Science ®Google Scholar
• Campbell S. L., Khosravi-Far R., Rossman K. L., Clark G. J., Der C. J. Increasing complexity of Ras signaling. Oncogene 1998; 17(11)1395–1413
   PubMed Web of Science ®Google Scholar
• Treisman R. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 1996; 8(2)205–215
   PubMed Web of Science ®Google Scholar
• Ambesi-Impiombato F. S., Parks L. A., Coon H. G. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc. Natl. Acad. Sci. USA 1980; 77(6)3455–3459
   PubMed Web of Science ®Google Scholar
• Fusco A., Portella G., Di Fiore P. P., Berlingieri M. T., Di Lauro R., et al. A mos oncogene-containing retrovirus, myeloproliferative sarcoma virus, transforms rat thyroid epithelial cells and irreversibly blocks their differentiation pattern. J. Virol. 1985; 56(1)284–292
   PubMed Web of Science ®Google Scholar
• Berlingieri M. T., Santoro M., Battaglia C., Grieco M., Fusco A. The adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. Oncogene 1993; 8(2)249–255
   PubMed Web of Science ®Google Scholar
• Estour B., Van Herle A. J., Juillard G. J., Totanes T. L., Sparkes R. S., et al. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1). Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1989; 57(3)167–174
   PubMedGoogle Scholar
• Basolo F., Giannini R., Toniolo A., Casalone R., Nikiforova M., et al. Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. Int. J. Cancer 2002; 97(5)608–614
   PubMed Web of Science ®Google Scholar
• Pang X. P., Hershman J. M., Chung M., Pekary A. E. Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 1989; 125(4)1783–1788
   PubMed Web of Science ®Google Scholar
• Tanaka J., Ogura T., Sato H., Hatano M. Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology 1987; 161(1)62–72
   PubMed Web of Science ®Google Scholar
• Fabien N., Fusco A., Santoro M., Barbier Y., Dubois P. M., Paulin C. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 1994; 73(8)2206–2212
   Google Scholar
• Grewal A., Conway A. Tools for analyzing microarray expression data. Journal of Lab Automation 2000; 5: 62–64
   Google Scholar
• Kristiansen G., Sammar M., Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J. Mol. Histol. 2004; 35(3)255–262
   PubMed Web of Science ®Google Scholar
• Aigner S., Sthoeger Z. M., Fogel M., Weber E., Zarn J., et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997; 89(9)3385–3395
   PubMed Web of Science ®Google Scholar
• Deblandre G. A., Marinx O. P., Evans S. S., Majjaj S., Leo O., et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J. Biol. Chem. 1995; 270(40)23860–23866
   PubMed Web of Science ®Google Scholar
• Zuber J., Tchernitsa O. I., Hinzmann B., Schmitz A. C., et al. A genome-wide survey of RAS transformation targets. Nat. Genet. 2000; 24(2)144–152
   PubMed Web of Science ®Google Scholar
• Tchernitsa O. I., Sers C., Zuber J., Hinzmann B., Grips M., et al. Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene 2004; 23(26)4536–4555
   PubMed Web of Science ®Google Scholar
• Brem R., Certa U., Neeb M., Nair A. P., Moroni C. Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model. Oncogene 2001; 20(22)2854–2858, Erratum in: Oncogene 2001 20 (35), 4916
   PubMed Web of Science ®Google Scholar